<DOC>
	<DOCNO>NCT02607254</DOCNO>
	<brief_summary>The purpose study assess safety efficacy treatment pregabalin patient idiopathic small fiber neuropathy proven skin biopsy.This enrich enrollment randomize withdrawal study comprise 4 phase : screen selection phase , washout period previous pain medication enrich enrollment , 8 week single blind pregabalin treatment phase ; 4 week randomize withdrawal phase .</brief_summary>
	<brief_title>Efficacy Safety Pregabalin Treatment Neuropathic Pain Patients With Idiopathic Small Fiber Neuropathy</brief_title>
	<detailed_description>Patients show increase pain intensity score washout phase eligible single blind pregabalin treatment phase . Patients respond pregabalin , least 1 point improvement neuropathic pain baseline end single blind pregabalin treatment phase meeting study requirement consider eligible participation withdrawal phase . These eligible patient randomly assign ( 1:1 ) continue pregabalin switch placebo comparison pregabalin efficacy safety . Patients worsen average pain relative last week single blind pregabalin treatment period one point average pain level &gt; =4 consider loss therapeutic response ( LTR ) .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Erythromelalgia</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Subjects idiopathic predominatesmall fiber neuropathy Subject must chronic peripheral neuropathic pain 3 month A score &gt; 3 &lt; 8 Pain intensity scale pain prior week first visit ; Show increase pain intensity score wash period ; Age old 18 year ; Subjects largefiber predominant neuropathy Subjects HIV infection , trigeminal neuralgia ( TGN ) , toxic neuropathy ( e.g . chemotherapy exposure ) , paraneoplastic neuropathy , monogammopathy , inflammatory neuropathy , celiac disease , systemic lupus , peripheral vascular disease , connective tissue disorder , hepatitis C , Fabry disease , diabetes ; Subjects uncontrolled thyroid B12 disorder Subjects Complex Regional Pain Syndrome Allergy Pregabalin Subjects risk suicide self harm Subjects clinically unstable cardiovascular , hematological , autoimmune , endocrine , renal , hepatic , renal , respiratory , gastrointestinal disease ; epilepsy , symptomatic peripheral vascular disease include intermittent claudication , pernicious anemia , untreated hypothyroidism , venous insufficiency , spinal stenosis . History known analgesic , alcohol illicit drug abuse within 12 month first visit ; Pregnant females ; breastfeed female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>